Ingenuity Systems and Erasmus Medical Center today announced a disease research collaboration to derive biological insights from NGS data. Ingenuity’s IPA software and the Ingenuity Knowledge Base allow researchers to realize the full potential of NGS datasets by placing the data in a relevant biological context. Erasmus has used IPA to sift through thousands of variants and discover a novel causal variant.
In the article, GEN explores the value that IPA is unlocking from NGS data for Erasmus researchers, who have used IPA to discover a novel causal variant. “Like many researchers, we faced the challenge of sifting through thousands of variants in order to rapidly identify the few that were the best candidates for follow-up studies and those most likely to be causal for our disease phenotype,” comments Erasmus professor Peter van der Spek, Ph.D. “IPA helped us overcome this challenge and discover a novel causal variant in a disease area of interest. It provides the critical biological context necessary to realize the full potential of NGS datasets, thanks to its high-quality, detailed biomedical content and powerful analysis capabilities.”
The press release about the collaboration with Erasmus comes shortly after other Ingenuity press releases announcing collaborations with several partners in the NGS space, including GenomeQuest, CLC bio, and Geospiza. Additionally, the upcoming release of IPA 9.0 will support RNA-Seq processed datasets containing Ensembl, RefSeq or UCSC IDs. Researchers will now be able to analyze and interpret their RNA-Seq data in the biological context of pathways and cellular and disease processes – a critical step to ensure that key insights are not missed and that researchers derive maximum value from their RNA-Seq experiments.
Read the GEN article: Erasmus University Claims Ingenuity’s IPA Software Maximizes Potential of NGS Data.